PERCIVIA LLC Appoints Dr. Michael Wyand Vice President, Global Operations and Nicholas Plumeridge Vice President, Global Business Development

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--PERCIVIA LLC, (“PERCIVIA”) named Dr. Michael Wyand the Vice President of Global Operations and Nicholas Plumeridge the Vice President of Global Business Development. PERCIVIA is a venture formed by Crucell N.V. and Royal DSM N.V., to develop recombinant therapeutic proteins using the PER.C6^® human cell line, with a focus on bio-similar monoclonal antibodies globally. Additionally, PERCIVIA outlicenses the PER.C6^®cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology provided to licensees.

“Michael brings an array of industry experience PERCIVIA. We are excited to have someone of Michael’s background lead our technical operations efforts”

Dr. Michael Wyand

Dr. Wyand will head global operations, including research, product development, and manufacturing for PERCIVIA. “Michael brings an array of industry experience PERCIVIA. We are excited to have someone of Michael’s background lead our technical operations efforts,” said Amit Munshi, President & CEO of PERCIVIA.

Michael joins PERCIVIA from BioAssets where he ran product development, research and development and manufacturing. He has been responsible for numerous INDs and BLAs as well as operations globally. While at BioAssets, Michael was a member of the executive team and responsible for manufacturing, quality, preclinical and clinical development. He led a product through all research and development functions to a multicenter Phase 2a clinical trials. Additionally, he executed global due diligence in the U.S., India and China on biosimilar partners for development and commercial supply agreements.

Prior to BioAssets, Michael was Sr. VP, Research and Development at Therion Corp where he led an R&D team of eighty in vaccine research, immunology, preclinical development, CMC strategy, process development, manufacturing, and compliance. He successfully moved two novel gene therapy cancer vaccines from discovery/preclinical through Phase 2 (prostate) and Phase 3 (pancreatic) and, in collaboration with the National Institutes of Health and the International Aids Vaccine Initiative, initiated Phase 1 AIDS vaccine studies in U.S. and India. He also developed the strategy and executed design, construction, and validation of cGMP manufacturing launch facility for Phase 3 and commercial production of lead products, completing construction and validation completed in two stages within 3 years. He conducted several successful CMC and IND submissions with the US FDA during his time at Therion.

Michael has a PhD in Pathology from University of Connecticut and a DVM from Purdue University.

Nicholas Plumeridge

Nicholas will be responsible for global business development for PERCIVIA. “Nick is a rare individual with a breadth of transaction experience in virtually every market globally and across multiple therapeutic areas”, said Amit Munshi, President & CEO of Percivia and Member, Board of Directors, PERCIVIA.

Nicholas joins PERCIVIA with 23 years of global business development experience (US, Europe, and Asia Pacific, including Japan, China, SE Asia, & Australia) with Serono, Aventis, Quintiles, and Invida Pharmaceuticals. Most recently Nick was with Takeda Pharmaceuticals where he was Head of Business Development & Licensing for Asia Pacific (ex Japan). Nick has led diligence and completed major deals ranging from multi B\billion dollar M&A’s (Nycomed, Valeant) to acquisition and in-licensing of specialized products and portfolio’s, life cycle management projects, partnerships and co-promotion deals. In over 30 major deals, Nick has in-licensed over 100 commercial stage assets for Asia, completed several large co-promotion deals in China with major pharmaceutical companies, and completed M&A due diligence on several major deals in Europe, China and SE Asia.

On the commercial side, Nick has general management experience at both country and regional level with specific expertise in emerging markets having established legal entities, built, developed and run several affiliates with direct management responsibility for 400+ staff.

Nick has a BS in Biology from the University of Essex (UK) and spent four years as an officer in the Royal Navy.

About PERCIVIA LLC

PERCIVIA LLC develops recombinant therapeutic proteins using the PER.C6^® human cell line, with a focus on bio-similar monoclonal antibodies globally. PERCIVIA has developed a highly efficient protein production platform based on the PER.C6^®cell line for the production of human therapeutic proteins with native human characteristics, at extremely high yields. The use of a host human cell line eliminates the risk of having non-human contaminants in biological products used for human therapy. Additionally, PERCIVIA outlicenses the PER.C6^® cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology provided to licensees. The PER.C6^® platform encompasses cell line generation technology, cell culture development, and downstream processes.

PERCIVIA LLC is a joint venture formed by Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Dutch biopharmaceutical company Crucell N.V. both headquartered in the Netherlands.

DSM – Bright Science. Brighter Living.™

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com

DSM Forward-Looking Statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that their expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.